stockportfolio.pro
Stocks / DMII vs NCDL
DMII vs NCDL
Drugs Made In America Acquisition II Corp. and Nuveen Churchill Direct Lending Corp. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Financial Services.
| Drugs Made In America Acquisition II Corp. (DMII) | Nuveen Churchill Direct Lending Corp. (NCDL) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $0 | $76.61M |
| Net income (latest FY) | $4.19M | $65.61M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | 85.6% |
| Return on equity | 0.9% | 7.5% |
| P/E ratio | 72.0 | 10.7 |
| Dividend yield | — | 11.2% |
| Profitable years (of last 10) | 1 | 5 |
| Positive free cash flow | — | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DMII — free Open NCDL — freeFrequently asked questions
Which is bigger, DMII or NCDL?
Drugs Made In America Acquisition II Corp. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, DMII or NCDL?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.